ImpediMed is a Listed company in ASX stock market exchange(IPD.AX). It is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technique for applications in the non-invasive clinical assessment and fluid status monitoring in patients. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphedema.